Iovance Biotherapeutics, Inc. IOVA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s stock issuance proceeds?
- Iovance Biotherapeutics, Inc. (IOVA) reported stock issuance proceeds of $98.51M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Iovance Biotherapeutics, Inc.'s stock issuance proceeds decreased by 33.9% year-over-year, from $148.94M to $98.51M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s stock issuance proceeds?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s stock issuance proceeds has grown at a 10.8% compound annual growth rate (CAGR), from $203.16M to $306.31M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.